Alpha Teknova vs Trinity Biotech
TKNO and TRIB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How TKNO and TRIB compare
Alpha Teknova grew revenue faster over the last twelve months (15.4% versus −28.9% for Trinity Biotech).
Alpha Teknova keeps more of each dollar of sales as profit, with a net margin of −34.8% compared with −85.4% at Trinity Biotech.
Alpha Teknova scores higher on the StockData Score (12 against 1 for Trinity Biotech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | TKNO | TRIB |
|---|---|---|
| Size and price | ||
| Market cap | $463M | – |
| Share price | $8.62 | $5.82 |
| Change, 1 year | 87.0% | −79.4% |
| Change, 5 years | −65.5% | −98.0% |
| Beta (5Y) | 1.19 | 1.43 |
| Employees | 158 | 287 |
| StockData Score | ||
| Total score | 12 (better) | 1 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 1 |
| Performance score | 3 (better) | 0 |
| Health score | 6 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 10.1× | – |
| P/B | 7.7× | – |
| FCF yield | −1.4% | – |
| Fair value | $3.45 | – |
| Margin of safety | −150% | – |
| Growth | ||
| Revenue growth (TTM) | 15.4% (better) | −28.9% |
| Revenue growth, 5Y average | 5.3% (better) | −15.6% |
| Profitability | ||
| Gross margin | 36.4% | 38.6% (better) |
| Operating margin | −32.7% (better) | −36.1% |
| Net margin | −34.8% (better) | −85.4% |
| FCF margin | −13.9% | −13.7% (better) |
| Return on equity | −24.1% | – |
| Return on invested capital | −25.3% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −0.7× |
| Current ratio | 3.56 (better) | 0.25 |
| Altman Z-score | 6.03 | – |
| Piotroski F-score | 6 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 17.0% | 0.01% |
| Held by insiders | 1.3% | 51.7% |
| Insider net buying, 12 months | $144K | – |
| Short interest, % of float | 2.9% | – |
Go deeper
- TKNO stock overview
- TKNO income statement
- TKNO valuation and score
- TRIB stock overview
- TRIB income statement
- TRIB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.